The consummation of the merger with Apellis Pharmaceuticals will require significant organizational restructuring to integrate operations, personnel, and technology platforms.
Filing excerpt
On May 14, 2026, Biogen Inc., a Delaware corporation (“Biogen”), filed a Current Report on Form 8-K (the “Original Report”) with the U.S. Securities and Exchange Commission.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8krestructuringGet every 8-K signal for Biogen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/20ad5873-2f00-4262-8b54-d3b944c68d86 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.
{
"signal_id": "20ad5873-2f00-4262-8b54-d3b944c68d86",
"signal_type": "sec-8k",
"signal_subtype": "restructuring",
"detected_at": "2026-06-16T09:38:01.33+00:00",
"company": {
"name": "Biogen",
"domain": "biogen.com"
},
"data": {
"detail": "The consummation of the merger with Apellis Pharmaceuticals will require significant organizational restructuring to integrate operations, personnel, and technology platforms. This event creates immediate opportunities for vendors specializing in systems integration, change management, and process optimization to address post-merger complexities.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "Biogen completes acquisition of Apellis Pharmaceuticals, triggering post-merger integration and restructuring.",
"excerpts": "On May 14, 2026, Biogen Inc., a Delaware corporation (“Biogen”), filed a Current Report on Form 8-K (the “Original Report”) with the U.S. Securities and Exchange Commission.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/875045/000095015726000699/form8-ka.htm",
"filing_date": "2026-06-10",
"filing_year": 2026,
"sales_relevance": "Change management needs",
"signal_category": "workforce"
}
}
curl https://signals.autobound.ai/v1/signals/20ad5873-2f00-4262-8b54-d3b944c68d86 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.